根據台灣事實查核中心,這批6月4號到台灣的AZ疫苗原液並非出包被撤銷生產資格的Emergent BioSolutions藥廠製造,是由Catalent藥廠製造的,可是國外的新聞,Catalent是疫苗原料的供應商以及幫Emergent BioSolutions完成的AZ疫苗裝瓶,國外消息轉移到Catalent生產AZ疫苗還在談判中???
----------------------------------------------------------
【報告將隨時更新 2021/7/7版】
一、傳言所提的事件為，美國製藥公司Emergent BioSolutions位於美國馬里蘭州巴爾的摩的工廠，於2021年3月發生AZ疫苗和嬌生疫苗原物料交叉污染事件。
二、日本捐贈台灣的AZ疫苗，其原液來自美國Catalent公司，不是美國製藥公司Emergent BioSolution。
https://tfc-taiwan.org.tw/articles/5956
--------------------------------------------------------------
2021年6月2日國外的新聞,AZ正在談判尋找新的廠商取代Emergent BioSolutions
June 2, 2021
WASHINGTON — The British-Swedish company AstraZeneca is negotiating with the federal government to shift production of its coronavirus vaccine from a troubled plant near Baltimore to a factory owned by the pharmaceutical company Catalent, according to people familiar with the government’s plans.
https://www.nytimes.com/2021/06/02/us/politics/astrazeneca-covid-vaccine.html
-------------------------------------------------------------
2021年7月6日國外新聞,AZ正在跟美國政府談判把疫苗生產轉移到Catalent
07.06.2021 - After losing Emergent BioSolutions as a Covid-19 vaccine production partner, AstraZeneca has been looking for a new CDMO to fulfil its $1.2 billion contract with the US Biomedical Advanced Research and Development Authority (BARDA). Citing people familiar with the matter, the newspaper New York Times reports that the Anglo-Swedish drugmaker is now in talks with the US government about transferring dose manufacture to Catalent.
AstraZeneca confirmed the talks to the Times, but declined to provide further details. An unidentified US official, however, told the newspaper that the government is renegotiating the Anglo-Swedish drugmaker’s contract in order to facilitate a production switch. A retrofitted line at Catalent in Harmans, Maryland, could turn out 25-35 million doses per month, the official said, similar to the volume Emergent was expected to produce.
https://www.chemanager-online.com/en/news/catalent-may-take-slack-astrazeneca-us
內文搜尋
從 APP 打開
X